Skip to search formSkip to main contentSkip to account menu

CHZ868

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AminopyridinesBenzimidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Faculty of 1000 evaluation for Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia.
2015
2015
Abstract A23: Type II JAK2 inhibitor NVP-CHZ868 has potent activity in JAK2-dependent B-cell acute lymphoblastic leukemias (B-ALLs) in vivo.
Approximately 10% of B-ALLs harbor CRLF2 rearrangements and have a poor prognosis. Although these leukemias are addicted to JAK2… 
2015
2015
Abstract IA41: Role of JAK-STAT pathway activation in MPN pathogenesis and therapeutic response.
The discovery of JAK2/MPL mutations in the majority of patients with Myeloproliferative Neoplasms (MPN) led to the development of… 
2014
2014
Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models
The identification of JAK2 mutations in patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)